Pyxis Oncology (NASDAQ:PYXS) Downgraded by Zacks Research to “Hold”

Pyxis Oncology (NASDAQ:PYXS) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

PYXS has been the topic of a number of other research reports. Guggenheim increased their target price on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday. Stifel Nicolaus started coverage on shares of Pyxis Oncology in a report on Monday. They issued a “buy” rating and a $9.00 price target on the stock. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Pyxis Oncology in a research note on Tuesday, August 19th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.40.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS opened at $3.91 on Tuesday. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.39. The firm has a 50-day simple moving average of $2.62 and a two-hundred day simple moving average of $1.68. The company has a market cap of $243.44 million, a P/E ratio of -2.44 and a beta of 1.41.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01. As a group, equities research analysts expect that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Several institutional investors have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd purchased a new position in Pyxis Oncology in the second quarter worth $26,000. Kingstone Capital Partners Texas LLC purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at $37,000. XTX Topco Ltd acquired a new stake in shares of Pyxis Oncology in the 2nd quarter worth $40,000. Velan Capital Investment Management LP purchased a new position in Pyxis Oncology during the 2nd quarter worth $44,000. Finally, Acadian Asset Management LLC acquired a new position in Pyxis Oncology during the 1st quarter valued at about $81,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.